Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 69,000 KRW
Change Today -900.00 / -1.29%
Volume 570.9K
068270 On Other Exchanges
As of 11:04 PM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).

celltrion inc (068270) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/26/15 - 76,400
52 Week Low
12/12/14 - 35,476
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CELLTRION INC (068270)

Related News

No related news articles were found.

celltrion inc (068270) Related Businessweek News

No Related Businessweek News Found

celltrion inc (068270) Details

Celltrion, Inc. is engaged in the research and development, and manufacture of biopharmaceutical products in South Korea and internationally. It develops and manufactures biosimilar monoclonal antibodies (mAbs) and therapeutics for oncology and autoimmune diseases. The company markets Remsima, a biosimilar mAb and tumor necrosis factor antagonist that is used to treat rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, adult Crohn’s disease, plaque psoriasis, and psoriatic arthritis. Its product pipeline includes CT-P6 for the treatment of breast cancer; CT-P10 for the treatment of non- Hodgkin’s lymphoma and rheumatoid arthritis; and CT-P27, a therapeutic antibody for treatment against universal influenza, which is in Phase IIA clinical trials. The company is also developing the mAbs for treatment of rabies in collaboration with Center for Disease Control and Prevention in the United States; antibodies against various virus subtypes and drug resistant hepatitis B viruses; Anti–GP88, mAbs for treatment of breast and lung cancer diseases; antibody-drug conjugate to treat and prevent influenza viruses; and biosimilar candidates for the treatment of colorectal and colon cancer, rheumatoid arthritis, and respiratory diseases. In addition, it offers contract manufacturing services to biopharmaceutical companies. Celltrion, Inc. was founded in 2002 and is headquartered in Incheon, South Korea.

Founded in 2002

celltrion inc (068270) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

celltrion inc (068270) Key Developments

Celltrion, Inc., Annual General Meeting, Mar 20, 2015

Celltrion, Inc., Annual General Meeting, Mar 20, 2015., at 10:00 Korea Standard Time. Location: Songdo Convensia Yeonsugu songdodong 6-1 second floor meeting room. Agenda: To consider approval of financial statements based on the second bill; to consider appointment of inside directors; to consider appointment of Audit Committee; to consider approval of director remuneration bill; and to consider approval of stock option grant.

Celltrion, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 07:30 AM

Celltrion, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 07:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Seung-Seo Hong, Executive Vice President.

Celltrion, Inc., Special/Extraordinary Shareholders Meeting, Dec 08, 2014

Celltrion, Inc., Special/Extraordinary Shareholders Meeting, Dec 08, 2014., at 10:00 Korea Standard Time. Location: Songdodong 6-1 gu. Agenda: To consider election of directors.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
068270:KS 69,000.00 KRW -900.00

068270 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 068270.
View Industry Companies

Industry Analysis


Industry Average

Valuation 068270 Industry Range
Price/Earnings 62.1x
Price/Sales 12.7x
Price/Book 4.8x
Price/Cash Flow 63.6x
TEV/Sales 13.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLTRION INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at